Your browser doesn't support javascript.
Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
He, Xuan; Chandrashekar, Abishek; Zahn, Roland; Wegmann, Frank; Yu, Jingyou; Mercado, Noe B; McMahan, Katherine; Martinot, Amanda J; Piedra-Mora, Cesar; Beecy, Sidney; Ducat, Sarah; Chamanza, Ronnie; Huber, Sietske Rosendahl; van Heerden, Marjolein; van der Fits, Leslie; Borducchi, Erica N; Lifton, Michelle; Liu, Jinyan; Nampanya, Felix; Patel, Shivani; Peter, Lauren; Tostanoski, Lisa H; Pessaint, Laurent; Van Ry, Alex; Finneyfrock, Brad; Velasco, Jason; Teow, Elyse; Brown, Renita; Cook, Anthony; Andersen, Hanne; Lewis, Mark G; Schuitemaker, Hanneke; Barouch, Dan H.
  • He X; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Chandrashekar A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Zahn R; Janssen Vaccines & Prevention BV, Leiden, the Netherlands.
  • Wegmann F; Janssen Vaccines & Prevention BV, Leiden, the Netherlands.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Mercado NB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • McMahan K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Martinot AJ; Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
  • Piedra-Mora C; Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
  • Beecy S; Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
  • Ducat S; Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
  • Chamanza R; Janssen Vaccines & Prevention BV, Leiden, the Netherlands.
  • Huber SR; Janssen Vaccines & Prevention BV, Leiden, the Netherlands.
  • van Heerden M; Janssen Vaccines & Prevention BV, Leiden, the Netherlands.
  • van der Fits L; Janssen Vaccines & Prevention BV, Leiden, the Netherlands.
  • Borducchi EN; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Lifton M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Liu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Nampanya F; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Patel S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Peter L; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Tostanoski LH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Pessaint L; Bioqual, Rockville, MD 20852, USA.
  • Van Ry A; Bioqual, Rockville, MD 20852, USA.
  • Finneyfrock B; Bioqual, Rockville, MD 20852, USA.
  • Velasco J; Bioqual, Rockville, MD 20852, USA.
  • Teow E; Bioqual, Rockville, MD 20852, USA.
  • Brown R; Bioqual, Rockville, MD 20852, USA.
  • Cook A; Bioqual, Rockville, MD 20852, USA.
  • Andersen H; Bioqual, Rockville, MD 20852, USA.
  • Lewis MG; Bioqual, Rockville, MD 20852, USA.
  • Schuitemaker H; Janssen Vaccines & Prevention BV, Leiden, the Netherlands.
  • Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA. Electronic address: dbarouch@bidmc
Cell ; 184(13): 3467-3473.e11, 2021 06 24.
Article in English | MEDLINE | ID: covidwho-1252548
ABSTRACT
We previously reported that a single immunization with an adenovirus serotype 26 (Ad26)-vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. To evaluate reduced doses of Ad26.COV2.S, 30 rhesus macaques were immunized once with 1 × 1011, 5 × 1010, 1.125 × 1010, or 2 × 109 viral particles (vp) Ad26.COV2.S or sham and were challenged with SARS-CoV-2. Vaccine doses as low as 2 × 109 vp provided robust protection in bronchoalveolar lavage, whereas doses of 1.125 × 1010 vp were required for protection in nasal swabs. Activated memory B cells and binding or neutralizing antibody titers following vaccination correlated with protective efficacy. At suboptimal vaccine doses, viral breakthrough was observed but did not show enhancement of disease. These data demonstrate that a single immunization with relatively low dose of Ad26.COV2.S effectively protected against SARS-CoV-2 challenge in rhesus macaques, although a higher vaccine dose may be required for protection in the upper respiratory tract.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Adenoviridae / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Animals Language: English Journal: Cell Year: 2021 Document Type: Article Affiliation country: J.cell.2021.05.040

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Adenoviridae / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Animals Language: English Journal: Cell Year: 2021 Document Type: Article Affiliation country: J.cell.2021.05.040